Moreover, specific targeting of NLRP3 (and not of the major anti-microbial inflammasomes NLRC4 and NLRP1) may explain why MCC950 is less immunosuppressive than biologic compounds (e.g., Canakinumab, which may clinically increase the risk of serious infections (8, 17). The gene discussed is NLRP1; the disease is infection.